Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04267250 · ClinicalTrials.gov registry record · Phase 1
Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04267250 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT04267250, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This Phase 1 study will assess the pharmacokinetic effect of multiple doses PF 06700841 (administered once a day) on a single dose of a combination oral contraceptive, in 18 healthy female participants who are not of childbearing potential.
Interventions
- DRUG Ethinyl estradiol (EE) and levonorgestrel (LN)
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04267250
The ClinicalTrials.gov registry entry for NCT04267250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ethinyl estradiol (EE) and levonorgestrel (LN) is the first listed.
NCT04267250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04267250 about?
NCT04267250 is a clinical study titled "Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids". This Phase 1 study will assess the pharmacokinetic effect of multiple doses PF 06700841 (administered once a day) on a single dose of a combination oral contraceptive, in 18 healthy female participants who are not of childbearing potential.
What is the current status of trial NCT04267250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-08-24. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT04267250?
The interventions under investigation include: Ethinyl estradiol (EE) and levonorgestrel (LN) (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT04267250?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.